Climb Bio Inc. Ordinary Shares CLYM 深 滬
交易中 10-29 11:15:38 美东时间
2.018
-0.062
-2.98%
華盛通- 最 高2.065
- 今 開2.05
- 成交量 11.37万股
- 最 低 2.00
- 昨 收 2.08
- 總市值 1.37亿
- 52周最高 4.34
- 市盈率 靜 --
- 換手率 0.17%
- 52周最低 1.05
- 委 比 -22.86%
- 總股本 6776.41万
- 歷史最高 29.69
- 量 比 0.90
- 振 幅 3.13%
- 歷史最低 1.05
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
Climb Bio appointed Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy. Their expertise will support the company's clinical development and operational efficiency. Villa brings over two decades of experience in biopharmaceutical development, while Jones has a proven track record in building high-performing teams. The company granted inducement equity awards to both exe...
10-21 11:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
10-21 05:08
Climb Bio Releases New Clinical Data on Budoprutug
Climb Bio ( ($CLYM) ) has shared an announcement. Climb Bio, Inc. announced on ...
10-17 19:28
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
Climb Bio, a biotech company, announced plans to present preclinical data on CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy (IgAN), and publish long-term clinical data on budoprutug, an anti-CD19 monoclonal antibody for primary membranous nephropathy (pMN), at the 2025 American Society of Nephrology Kidney Week. CLYM116 showed promising pharmacokinetic and pharmacodynamic properties in preclinical models, while budoprutug demonstr...
10-17 11:00
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Analysts’ Top Healthcare Picks: Climb Bio (CLYM), Wave Life Sciences (WVE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
10-16 19:20
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
HC Wainwright & Co. Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $9
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $9.
10-13 19:21
Climb Bio Appoints New CFO Susan Altschuller
Climb Bio ( ($CLYM) ) has issued an update. Climb Bio, Inc. announced the appoi...
10-02 05:48
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
